Archimedes Pharma was a European specialty pharmaceutical company focused on the development and commercialization of novel, patient-focused medicines in areas such as pain, oncology, and critical care. Founded in 2004, the company grew its portfolio through product development and strategic acquisitions. Archimedes Pharma was acquired by ProStrakan Group plc (which later became part of Kyowa Kirin International) in 2012. Its flagship product, PecFent®, a fentanyl nasal spray for breakthrough cancer pain, was a key asset in its portfolio.
The Reading headquarters served as the central hub for Archimedes Pharma's corporate functions, including executive management, R&D oversight, commercial strategy, business development, and administrative operations for its European activities before its acquisition.
As a tenant in a modern business park facility (Merlin House), notable features would have been contemporary office amenities supporting a dynamic work environment, rather than unique architectural highlights specific to Archimedes Pharma's occupancy.
The work culture at Archimedes Pharma was likely dynamic and entrepreneurial, focused on innovation in specialty pharmaceuticals, patient outcomes, and achieving rapid growth in competitive European markets. A collaborative and results-driven approach would have been characteristic.
The Reading headquarters was pivotal as the operational and strategic core for Archimedes Pharma during its phase of significant product development, market expansion, and ultimately, its acquisition, solidifying its role in the European specialty pharma sector.
Prior to its acquisition in 2012, Archimedes Pharma established a significant operational presence across Europe. The company had direct commercial operations and subsidiaries in major markets including the United Kingdom, Germany, France, and Spain. Its primary focus was on the development, registration, and commercialization of its specialty pharmaceutical products within these European territories. While its products addressed global medical needs, its direct commercial infrastructure was concentrated in Europe.
Merlin House, Brunel Road, Theale
Reading
Berkshire
United Kingdom
Address: Specific national office addresses varied; typically located in commercial/business districts.
To drive commercial success of Archimedes Pharma's portfolio in key European markets, adapting global strategies to local healthcare systems, and engaging with local medical communities and authorities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Archimedes Pharma' leadership includes:
Archimedes Pharma has been backed by several prominent investors over the years, including:
Executive activities at Archimedes Pharma in its final years as an independent company were largely focused on product commercialization, growth, and the strategic process leading to its acquisition by ProStrakan Group (now Kyowa Kirin) in 2012. Key leadership successfully navigated the company through this transition.
Discover the tools Archimedes Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
As Archimedes Pharma was acquired in 2012 and its operations integrated into ProStrakan (now Kyowa Kirin), its original email domain (archimedespharma.com) is no longer active. Historically, companies like Archimedes Pharma commonly used email formats such as [first_initial][last]@[domain.com] or [first].[last]@[domain.com].
Likely [first_initial][last]@archimedespharma.com (e.g., rhigham@archimedespharma.com) or [first].[last]@archimedespharma.com (e.g., richard.higham@archimedespharma.com)
Format
example@archimedespharma.com (Note: This domain is inactive)
Example
0%
Success rate
Business Wire • March 27, 2012
ProStrakan Group plc announced it agreed to acquire Archimedes Pharma Limited, a fast-growing European specialty pharmaceutical company, for up to £230 million. The acquisition aimed to significantly enhance ProStrakan's scale and strengthen its specialty pharma business in Europe, with PecFent being a key product....more
pharmatimes.com • September 10, 2010
Archimedes Pharma received European Commission approval for PecFent (fentanyl pectin nasal spray) for treating breakthrough cancer pain in adults already on opioid therapy. This pan-European marketing authorisation was a major milestone for the company....more
fiercebiotech.com (referencing original announcements) • February 4, 2004
Archimedes Pharma was launched as a new specialty pharmaceutical company with an initial £20 million ($37 million) in funding from a syndicate of venture capital firms including Warburg Pincus and Novo A/S. The company aimed to develop and commercialize drugs for specialist-driven markets....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Archimedes Pharma, are just a search away.